We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Axsome (AXSM) Up 14.7% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Axsome Therapeutics (AXSM - Free Report) . Shares have added about 14.7% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Axsome due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Axsome's Q1 Earnings Beat Estimates, Revenues Nil
Axsome incurred a loss of 78 cents per share in the first quarter of 2021, narrower than the Zacks Consensus Estimate of a loss of 83 cents per share and also the year-ago quarter’s loss of 88 cents.
Axsome currently does not have any approved product in its portfolio. As a result, the company is yet to generate revenues from the same.
Quarter in Detail
Research and development (R&D) expenses were $16.6 million in the quarter, down 39.6% from the year-ago period owing to completion of several studies on the pipeline candidates.
General and administrative (G&A) expenses were $11.2 million, up 124% year over year. The significant increase was due to higher pre-commercialization activities to support the anticipated launch of AXS-05 in the second half as well as increased stock compensation expenses and personnel costs.
As of Mar 31 2021, Axsome had cash worth $164.7 million compared with $183.9 million as of Dec 31, 2020. Management believes that its cash balance as of March-end along with $225 million worth term-loan facility will be enough to fund its anticipated operations at least through 2024.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision flatlined during the past month. The consensus estimate has shifted 6.41% due to these changes.
VGM Scores
Currently, Axsome has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Axsome has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Axsome (AXSM) Up 14.7% Since Last Earnings Report?
It has been about a month since the last earnings report for Axsome Therapeutics (AXSM - Free Report) . Shares have added about 14.7% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Axsome due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Axsome's Q1 Earnings Beat Estimates, Revenues Nil
Axsome incurred a loss of 78 cents per share in the first quarter of 2021, narrower than the Zacks Consensus Estimate of a loss of 83 cents per share and also the year-ago quarter’s loss of 88 cents.
Axsome currently does not have any approved product in its portfolio. As a result, the company is yet to generate revenues from the same.
Quarter in Detail
Research and development (R&D) expenses were $16.6 million in the quarter, down 39.6% from the year-ago period owing to completion of several studies on the pipeline candidates.
General and administrative (G&A) expenses were $11.2 million, up 124% year over year. The significant increase was due to higher pre-commercialization activities to support the anticipated launch of AXS-05 in the second half as well as increased stock compensation expenses and personnel costs.
As of Mar 31 2021, Axsome had cash worth $164.7 million compared with $183.9 million as of Dec 31, 2020. Management believes that its cash balance as of March-end along with $225 million worth term-loan facility will be enough to fund its anticipated operations at least through 2024.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision flatlined during the past month. The consensus estimate has shifted 6.41% due to these changes.
VGM Scores
Currently, Axsome has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Axsome has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.